[go: up one dir, main page]

WO2001022978A3 - Autologous marrow stem cell (msc) transplantation for myocardial regeneration - Google Patents

Autologous marrow stem cell (msc) transplantation for myocardial regeneration Download PDF

Info

Publication number
WO2001022978A3
WO2001022978A3 PCT/CA2000/001114 CA0001114W WO0122978A3 WO 2001022978 A3 WO2001022978 A3 WO 2001022978A3 CA 0001114 W CA0001114 W CA 0001114W WO 0122978 A3 WO0122978 A3 WO 0122978A3
Authority
WO
WIPO (PCT)
Prior art keywords
mscs
patient
further comprise
implanted
msc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2000/001114
Other languages
French (fr)
Other versions
WO2001022978A2 (en
Inventor
Ray C J Chiu
Dominique Shum-Tim
Jacques Galipeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to AU75004/00A priority Critical patent/AU7500400A/en
Priority to EP00963823A priority patent/EP1221956A2/en
Publication of WO2001022978A2 publication Critical patent/WO2001022978A2/en
Publication of WO2001022978A3 publication Critical patent/WO2001022978A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention relates to a method of improving cardiac function in a patient with heart failure without eliciting an immune response and without sacrificing the patient's skeletal muscle; which comprises the step of transplanting autologous bone marrow stroma cells (MSCs) into said patient's myocardium to grow new muscle fibers. The method may further comprise the step of using cell labeling technique to confirm survival and differentiation of implanted MSCs, and to identify said MSCs phenotype by both morphology and molecular markers. The method may further comprise examining the effects of the micro-environment of implanted MSCs on their differentiation and phenotype expression. The method may further comprise examining functional contribution of MSCs implanted into an ischemic segment of the myocardium.
PCT/CA2000/001114 1999-09-30 2000-09-28 Autologous marrow stem cell (msc) transplantation for myocardial regeneration Ceased WO2001022978A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU75004/00A AU7500400A (en) 1999-09-30 2000-09-28 Autologous marrow stem cell (msc) transplantation for myocardial regeneration
EP00963823A EP1221956A2 (en) 1999-09-30 2000-09-28 Autologous marrow stem cell (msc) transplantation for myocardial regeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15670099P 1999-09-30 1999-09-30
US60/156,700 1999-09-30

Publications (2)

Publication Number Publication Date
WO2001022978A2 WO2001022978A2 (en) 2001-04-05
WO2001022978A3 true WO2001022978A3 (en) 2001-08-16

Family

ID=22560676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001114 Ceased WO2001022978A2 (en) 1999-09-30 2000-09-28 Autologous marrow stem cell (msc) transplantation for myocardial regeneration

Country Status (3)

Country Link
EP (1) EP1221956A2 (en)
AU (1) AU7500400A (en)
WO (1) WO2001022978A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516242A (en) * 2000-07-26 2004-06-03 サイムド ライフ システムズ， インコーポレイテッド Therapeutic angiogenesis by transplanting bone marrow-derived cells into ischemic tissue of the heart and skeletal muscle
JP2004535199A (en) 2001-07-12 2004-11-25 ジェロン コーポレイション Cardiomyocyte lineage cells produced from human pluripotent stem cells
US7732199B2 (en) 2001-07-12 2010-06-08 Geron Corporation Process for making transplantable cardiomyocytes from human embryonic stem cells
DK1479767T3 (en) 2002-02-06 2013-11-25 Sanbio Inc Method of differentiating / inducing bone marrow to nerve cells by transferring Notch gene
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
RU2266125C1 (en) * 2004-03-29 2005-12-20 ГУ Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Method for treating acute myocardial infarction at st segment lifting
RU2250772C1 (en) * 2004-07-16 2005-04-27 Центральный научно-исследовательский рентгено-радиологический институт МЗ РФ (ЦНИРРИ) Method for treating the cases of non-operable cardiologic patients
AU2006220696B2 (en) 2005-03-07 2010-08-19 Sanbio, Inc. Use of neuronal precursor cells for treatment of central nervous system lesions
EP1885185A4 (en) * 2005-05-09 2010-04-07 Mytogen Inc Cellular cardiomyoplasty as supportive therapy in patients with heart disease
CN101228264B (en) 2005-06-22 2017-12-26 阿斯特利亚斯生物治疗股份公司 PPS is set to be divided into cardiomyocyte-lineage cells
WO2007021210A1 (en) * 2005-08-15 2007-02-22 Krasnozhenyuk Alexei Dmitrievi Method for treating diseases caused by vascular diseases
CN101939418A (en) 2008-01-30 2011-01-05 杰龙公司 Synthetic surfaces for culturing stem cell-derived cardiomyocytes
EP2485741A4 (en) * 2009-10-06 2013-07-24 Cohen Mcniece Foundation Preparation and use of stromal cells for treatment of cardiac diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
WO1999003973A1 (en) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
WO1999003973A1 (en) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRUDER S P ET AL: "MESENCHYMAL STEM CELLS IN BONE DEVELOPMENT, BONE REPAIR, AND SKELETAL REGENERATION THERAPY", JOURNAL OF CELL BIOLOGY,US,ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, vol. 56, no. 3, 1994, pages 283 - 294, XP000865959, ISSN: 0021-9525 *
FERRARI G ET AL: "Muscle regeneration by bone marrow -derived myogenic progenitors [see comments] [published erratum appears in Science 1998 Aug 14;281(5379):923]", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 279, 6 March 1998 (1998-03-06), pages 1528 - 1530, XP002098163, ISSN: 0036-8075 *
KESSLER P D ET AL: "MYOBLAST CELL GRAFTING INTO HEART MUSCLE: CELLULAR BIOLOGY AND POTENTIAL APPLICATIONS", ANNUAL REVIEW OF PHYSIOLOGY,US,ANNUAL REVIEWS, INC., PALO ALTO, CA, vol. 61, 1999, pages 219 - 242, XP000865708, ISSN: 0066-4278 *
MAKINO S. ET AL: "Cardiomyocytes can be generated from marrow stromal cells in vitro", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 103, no. 5, March 1999 (1999-03-01), pages 697 - 705, XP000990317 *
PROCKPO D. ET AL: "Marrow stromal cells for nonhematopoietic tissues", SCIENCE, vol. 276, 1997, pages 71 - 74, XP002162972 *
TOMITA S ET AL: "AUTOTRANSPLANTED MESENCHYMAL STEM CELLS IMPROVE FUNCTION AFTER A MYOCARDIAL INFARCATION", CIRCULATION,US,AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 98, no. SUPPL. 17, 1998, pages ABS1036, XP000870314, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
EP1221956A2 (en) 2002-07-17
AU7500400A (en) 2001-04-30
WO2001022978A2 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
WO2001022978A3 (en) Autologous marrow stem cell (msc) transplantation for myocardial regeneration
KR101733137B1 (en) Method of production for 3D cartilage organoid block
US6713245B2 (en) Methods for storing neural cells such that they are suitable for transplantation
US20030078653A1 (en) Tissue engineered mitral valve chordae and methods of making and using same
RU2012122055A (en) REMOVING AND RESTORING THE CELL CONTENT IN BODIES AND TISSUES
KR970704481A (en) COMPOSITIONS AND METHODS FOR A BIOARTIFICIAL EXTRACELLULAR MATRIX
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
KR20140139060A (en) Tissue-engineered heart valve for transcatheter repair
BR0214217A (en) Increased Organ Function
ES2004281A6 (en) Method of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial cell growth, and the surface itself
JP2012139541A (en) Three-dimensional tissue structure
WO2001007568A3 (en) Muscle cells and their use in cardiac repair
BR8602659A (en) IMPLANTABLE PROTECTIVE SURFACE FOR IMPLANTATION IN A HUMAN PATIENT AND PROCESS TO TREAT AN IMPLANT INTENDED FOR IMPLANTATION IN A HUMAN PATIENT
ATE295875T1 (en) METHOD FOR PRODUCING BONE IN VITRO
WO2002019893A3 (en) Improved cardiac function through administration of es cells
WO2007087519A3 (en) Mesenchymal stem cell isolation and transplantation method and system to be used in a clinical setting
WO2002083864A3 (en) Methods and reagents for cell transplantation
WO2002024244A3 (en) Method of preparing and processing transplant tissue
Mayer Jr In search of the ideal valve replacement device
Naimi et al. Ontogeny of human striatal DARPP-32 neurons in fetuses and following xenografting to the adult rat brain
CA2272130A1 (en) Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
HK1041442A1 (en) Composition and method for improving function of embryonic kidney transplants
JP2006514097A5 (en)
KR102767137B1 (en) Reduced elastin allowing recellularization of cartilage implants
Trainini et al. Autologous cellular cardiac-implant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000963823

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000963823

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10089710

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000963823

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP